Readers will learn how veterinary oncologists stage and treat canine lymphoma using modern multi-agent chemotherapy and ...

Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable, and many patients achieve long-term remission after ...

CEO Richard Adcock used a presentation at the Citizens Life Sciences Conference to outline the company’s commercial progress ...

Epcoritamab can now be accessed as an option to treat relapsed or refractory follicular lymphoma in adults after 2 or more lines of systemic treatment, only if epcoritamab is stopped after 3 years of ...

Ipsen has pulled Tazverik from all markets after a trial found risks of secondary blood cancers, affecting patients with ...

Joshua Abbott-Littler had only rang the bell at the Christie a year before to celebrate getting the "all clear" from his cancer diagnosis ...

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...

“Many confounding factors in real life—including lifestyle, UV exposure, occupational hazards, and immune status—can influence cancer risk,” says Tung. “As with many environmental exposures, ...

Ipsen initiated an immediate, worldwide withdrawal of the EZH2 inhibitor tazemetostat across follicular lymphoma and epithelioid sarcoma due to emerging safety signals. An independent data monitoring ...

PARIS, FRANCE, 09 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision ...